186 related articles for article (PubMed ID: 31905966)
61. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
Peng F; Xiong L; Peng C
Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
[TBL] [Abstract][Full Text] [Related]
62. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
63. Secreted Factors from Adipose Tissue Reprogram Tumor Lipid Metabolism and Induce Motility by Modulating PPARα/ANGPTL4 and FAK.
Blücher C; Iberl S; Schwagarus N; Müller S; Liebisch G; Höring M; Hidrobo MS; Ecker J; Spindler N; Dietrich A; Burkhardt R; Stadler SC
Mol Cancer Res; 2020 Dec; 18(12):1849-1862. PubMed ID: 32859692
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Kolev VN; Tam WF; Wright QG; McDermott SP; Vidal CM; Shapiro IM; Xu Q; Wicha MS; Pachter JA; Weaver DT
Oncotarget; 2017 Aug; 8(31):51733-51747. PubMed ID: 28881682
[TBL] [Abstract][Full Text] [Related]
65. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Vishwanatha JK; Mathew PA
Am J Cancer Res; 2018; 8(6):1050-1063. PubMed ID: 30034942
[TBL] [Abstract][Full Text] [Related]
66. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
67. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
68. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):87. PubMed ID: 29615063
[TBL] [Abstract][Full Text] [Related]
69. Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration
Scagliotti A; Capizzi L; Cazzaniga ME; Ilari A; De Giorgi M; Cordani N; Gallazzi M; Bruno A; Pelosi G; Albini A; Lavitrano M; Grassilli E; Cerrito MG
Front Oncol; 2022; 12():998274. PubMed ID: 36531071
[TBL] [Abstract][Full Text] [Related]
70. MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells.
Huang F; Wang B; Zeng J; Sang S; Lei J; Lu Y
Oncol Lett; 2018 Apr; 15(4):4797-4804. PubMed ID: 29552119
[TBL] [Abstract][Full Text] [Related]
71. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
Li J; Chen L; Xiong Y; Zheng X; Xie Q; Zhou Q; Shi L; Wu C; Jiang J; Wang H
Cell Physiol Biochem; 2017; 41(3):907-920. PubMed ID: 28222426
[TBL] [Abstract][Full Text] [Related]
72. [The Effects of PKCι on Anti-tumor Activity of Cytokine-induced Killer Cells Against Pancreatic Cancer Cells and the Possible Underlying Mechanisms].
Zhang HM; Wang YR; Yang JH; Leng XH; Wang PP; Li ZX; Zhu TB
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):821-826. PubMed ID: 31880112
[TBL] [Abstract][Full Text] [Related]
73. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
74. Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.
Ruiu R; Barutello G; Arigoni M; Riccardo F; Conti L; Peppino G; Annaratone L; Marchiò C; Mengozzi G; Calogero RA; Cavallo F; Quaglino E
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672732
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
Jinih M; Wang JH; Pfirrmann RW; O'Leary DP; Corrigan MA; Redmond HP
Anticancer Res; 2021 May; 41(5):2247-2256. PubMed ID: 33952451
[TBL] [Abstract][Full Text] [Related]
76. Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.
Huang K; Sun B; Luo N; Guo H; Hu J; Peng J
Med Sci Monit; 2018 Jul; 24():4573-4582. PubMed ID: 29967316
[TBL] [Abstract][Full Text] [Related]
77. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
78. β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer.
Yin HL; Wu CC; Lin CH; Chai CY; Hou MF; Chang SJ; Tsai HP; Hung WC; Pan MR; Luo CW
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589736
[TBL] [Abstract][Full Text] [Related]
79. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
[No Abstract] [Full Text] [Related]
80. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
